# Oragenics Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Oragenics Inc). ## Overview Oragenics Inc. is a U.S.-based biopharmaceutical development company focused on neurology assets, with its lead program ONP-002 being developed for the treatment of mild traumatic brain injury (concussion). The company operates as a single reportable segment centered on research, nonclinical work, clinical development, and regulatory advancement of its product candidate pipeline. ## Products & services • ONP-002 concussion treatment candidate • Neurology asset development • Nonclinical research and studies • Clinical trial planning and execution • Regulatory submission and IND-enabling work - **Lead product candidate development** (100%) — Development activities for ONP-002, the company's lead neurology candidate for concussion. - **Clinical research services** (0%) — Third-party clinical trial, manufacturing, and regulatory services used to advance the program. - **Nonclinical research and development** (0%) — Internal and outsourced preclinical studies and discovery work supporting the pipeline. - ONP-002 concussion treatment candidate - Neurology asset development - Nonclinical research and studies - Clinical trial planning and execution - Regulatory submission and IND-enabling work ## Customers Oragenics does not currently sell commercial products, so its direct counterparties are primarily clinical research organizations, manufacturing and regulatory service providers, and potential licensing or strategic partners. If ONP-002 advances, the end market would be patients and healthcare providers treating concussion and other mild traumatic brain injury cases. - **Clinical research and development vendors** (primary) — They provide trial execution, manufacturing, and regulatory support for ONP-002 development. - **Strategic licensing and partnership counterparties** (primary) — Potential partners that could fund, co-develop, or commercialize neurology assets. - **Future neurology patients and healthcare providers** (emerging) — The eventual end users of a concussion treatment if the candidate reaches market. - Clinical research vendors supporting trials and study operations - Manufacturing partners providing drug substance and trial materials - Regulatory and compliance service providers - Potential licensing partners and strategic collaborators - Future patients and clinicians if ONP-002 is commercialized ## Geography Oragenics is headquartered in the United States and its development activities are managed as a single operating segment without separate geographic reporting. The company’s business is tied to U.S. capital markets, U.S. clinical development, and U.S. regulatory pathways, while any future commercialization could extend to other markets through partners. - Headquartered in the United States - Clinical and regulatory work is organized as one operating segment - No separate geographic revenue disclosure because there is no revenue - U.S. capital markets are important for funding development - Future commercialization could be licensed into other regions ## Strategy The company’s strategy is to advance ONP-002 through clinical development and IND-enabling work while seeking external capital and strategic partnerships to support the program. It also references licensing, joint ventures, and other business arrangements as ways to fund development and expand the pipeline. - **Advance ONP-002 clinical development** (short-term) — The lead asset is the core value driver and the basis for future partnering or commercialization. - **Secure external funding and partnerships** (short-term) — Development requires capital and the company relies on financing or collaborations to continue operations. - **Build a broader neurology pipeline** (medium-term) — Additional assets can diversify scientific risk and create more partnering opportunities. - Advance ONP-002 through Phase II and IND-enabling work - Use third-party clinical and regulatory support to progress the program - Seek strategic partnerships and licensing deals - Pursue equity and debt financing to fund development - Maintain optionality for acquisitions or complementary assets ## Risks Oragenics faces the typical risks of a clinical-stage biotechnology company: uncertain trial outcomes, regulatory delays, and dependence on external financing. The company also highlights dilution risk from equity issuance, convertible securities, and anti-dilution features, which can materially affect shareholders as it funds development. - **Clinical development failure** [high] — ONP-002 is still in development, so efficacy, safety, or trial design issues could halt progress. - **Regulatory approval delay or denial** [high] — The business depends on IND-enabling work and future clinical/regulatory milestones. - **Financing dilution** [high] — The company expects to raise capital through equity and debt, which can dilute existing holders. - **Anti-dilution and conversion overhang** [medium] — Series H Preferred Stock terms may increase the number of shares issued on conversion. - **Partnering and licensing execution risk** [medium] — Future funding and development plans depend partly on external alliances and agreements. - Clinical trial failure or delay could impair the lead program - Regulatory approval risk is high for an early-stage drug candidate - Dependence on equity and debt financing creates dilution risk - Convertible preferred stock and warrants can increase share count - Partnership or licensing execution risk could limit funding options ## Accounting As a clinical-stage company with no product revenue, Oragenics’ reported results are driven mainly by research and development expense, general and administrative costs, and financing-related items. Investors should watch estimates around legal accruals, fair value or discount accounting on financing instruments, and going-concern disclosures because these can materially affect the balance sheet and loss presentation. - **Going concern assessment** — Can affect disclosure, investor perception, and liquidity analysis - **Research and development expense timing** — Drives quarter-to-quarter volatility in operating loss - **Legal and professional fee accruals** — Can materially affect G&A expense and liabilities - **Debt discount and interest expense** — Affects interest expense and net loss - **Convertible preferred stock and warrants** — Can affect equity classification, share count, and dilution - No revenue recognition yet because the company does not sell products - R&D expense depends on clinical, nonclinical, and third-party service timing - G&A can swing with legal, audit, regulatory, and public-company costs - Promissory note discount and financing costs affect interest and net loss - Accruals and contingencies can materially change reported liabilities --- *Last updated: 2026-04-29T04:43:08.503132+00:00*